Regenacy Pharmaceuticals
Dr. Yan is the Operating Partner at 3E Bioventures Capital and currently the General Manager of N.B. Quadriga, a joint venture biotechnology company developing first-in-class therapeutics for brain tumors. He has 17 years of pharmaceutical research and development and operation experience in both U.S. and China, having held positions with increasing responsibilities in Novartis, Roche, and GlaxoSmithKline. Dr. Yan has broad experience in various disease areas including oncology, neurosciences, and infectious diseases, and has close to 50 publications and patents. He received his B.Sc. in Physics from Fudan University and Ph.D. in Chemical Biology from New York University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Regenacy Pharmaceuticals
Regenacy Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment of diabetic and other peripheral neuropathies and other chronic conditions. The company’s selective inhibition technology provides superior safety profiles and potential enhanced efficacy compared to non-selective HDAC inhibitors. Regenacy selectively inhibits histone deacetylase 6 (HDAC6) to restore normal intracellular protein and organelle transport in peripheral neuropathies, and also has a portfolio of selective HDACs 1 and 2 inhibitors that have potential to treat major blood diseases such as leukemia, sickle cell disease, β-thalassemia, and cognitive dysfunction in neurological disorders.